Chemokines and HIV-1 second receptors: The therapeutic connection

[1]  S. Hammer,et al.  Potent Inhibition of Human Immunodeficiency Virus Type 1 in Primary T Cells and Alveolar Macrophages by a Combination Anti-Rev Strategy Delivered in an Adeno-Associated Virus Vector , 1998, Journal of Virology.

[2]  J J Goedert,et al.  Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC) , 1998, Science.

[3]  B. Korber,et al.  A new classification for HIV-1 , 1998, Nature.

[4]  R. Doms,et al.  The CC Chemokine I-309 Inhibits CCR8-dependent Infection by Diverse HIV-1 Strains* , 1998, The Journal of Biological Chemistry.

[5]  A. Trkola,et al.  Genetic Subtype-Independent Inhibition of Human Immunodeficiency Virus Type 1 Replication by CC and CXC Chemokines , 1998, Journal of Virology.

[6]  S. Mummidi,et al.  The Human CC Chemokine Receptor 5 (CCR5) Gene , 1997, The Journal of Biological Chemistry.

[7]  R. Doms,et al.  Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses , 1997, Journal of virology.

[8]  J. Hoxie,et al.  Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes. , 1997, Science.

[9]  E. Fenyö,et al.  In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression , 1997, Nature Medicine.

[10]  A. Garzino-Demo,et al.  Inhibition of HIV-1 Infection by the β-Chemokine MDC , 1997 .

[11]  R. Doms,et al.  A Small-molecule Inhibitor Directed against the Chemokine Receptor CXCR4 Prevents its Use as an HIV-1 Coreceptor , 1997, The Journal of experimental medicine.

[12]  C. Mackay,et al.  Interaction of Chemokine Receptor CCR5 with its Ligands: Multiple Domains for HIV-1 gp120 Binding and a Single Domain for Chemokine Binding , 1997, The Journal of experimental medicine.

[13]  E. Clercq,et al.  Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4 , 1997, The Journal of experimental medicine.

[14]  N. Yoshida,et al.  A Small Molecule CXCR4 Inhibitor that Blocks T Cell Line–tropic HIV-1 Infection , 1997, The Journal of experimental medicine.

[15]  A. Yang,et al.  Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy , 1997, Nature Medicine.

[16]  G P Nolan,et al.  Harnessing Viral Devices as Pharmaceuticals: Fighting HIV-1's Fire with Fire , 1997, Cell.

[17]  J. Rose,et al.  Construction of a Novel Virus That Targets HIV-1-Infected Cells and Controls HIV-1 Infection , 1997, Cell.

[18]  S. Finke,et al.  A CXCR4/CD4 Pseudotype Rhabdovirus That Selectively Infects HIV-1 Envelope Protein-Expressing Cells , 1997, Cell.

[19]  L. Picard,et al.  Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses , 1997, Journal of virology.

[20]  W. Marasco,et al.  Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kappa B antagonists , 1997, Journal of virology.

[21]  Ying Sun,et al.  Two Orphan Seven-Transmembrane Segment Receptors Which Are Expressed in CD4-positive Cells Support Simian Immunodeficiency Virus Infection , 1997, The Journal of experimental medicine.

[22]  K. Peden,et al.  A new SIV co-receptor, STRL33 , 1997, Nature.

[23]  D. Littman,et al.  Expression cloning of new receptors used by simian and human immunodeficiency viruses , 1997, Nature.

[24]  T. Bonner,et al.  Brief Definitive Report Identification of CCR8: A Human Monocyte and Thymus Receptor for the CC Chemokine I-309 , 2022 .

[25]  N. Heveker,et al.  Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. , 1997, Science.

[26]  A. Trkola,et al.  HIV type 1 coreceptors, neutralization serotypes, and vaccine development. , 1997, AIDS research and human retroviruses.

[27]  K. Peden,et al.  STRL33, A Novel Chemokine Receptor–like Protein, Functions as a Fusion Cofactor for Both Macrophage-tropic and T Cell Line–tropic HIV-1 , 1997, The Journal of experimental medicine.

[28]  Nancy Sullivan,et al.  CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophage-tropic HIV-1, In Vitro , 1997, The Journal of experimental medicine.

[29]  R. Weiss,et al.  CD4-independent infection by HIV-2 (ROD/B): use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry. , 1997, Virology.

[30]  C. Broder,et al.  Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[31]  B. Levine,et al.  Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. , 1997, Science.

[32]  T. Schwartz,et al.  Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. , 1997, Science.

[33]  J. Moore.  Coreceptors--Implications for HIV Pathogenesis and Therapy , 1997, Science.

[34]  J. Sodroski,et al.  Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239 , 1997, Journal of virology.

[35]  R. Connor,et al.  Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.

[36]  Wei Wang,et al.  A new class of membrane-bound chemokine with a CX3C motif , 1997, Nature.

[37]  J. Hoxie,et al.  CD4-independent association between HIV-1 gp120 and CXCR4: functional chemokine receptors are expressed in human neurons , 1997, Current Biology.

[38]  R. Weiss,et al.  Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry , 1996, Journal of virology.

[39]  V. Harden,et al.  Chemokines and HIV–1 second receptors , 1996, Nature Medicine.

[40]  R. Steinman,et al.  Efficient Interaction of HIV-1 with Purified Dendritic Cells via Multiple Chemokine Coreceptors , 1996, The Journal of experimental medicine.

[41]  R. Doms,et al.  CD4-Independent Infection by HIV-2 Is Mediated by Fusin/CXCR4 , 1996, Cell.

[42]  Steven M. Wolinsky,et al.  The role of a mutant CCR5 allele in HIV–1 transmission and disease progression , 1996, Nature Medicine.

[43]  D. Ho,et al.  HIV-1 subtype and second-receptor use , 1996, Nature.

[44]  M. Baggiolini,et al.  HIV blocked by chemokine antagonist , 1996, Nature.

[45]  J J Goedert,et al.  Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.

[46]  Bernhard Moser,et al.  The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 , 1996, Nature.

[47]  M. Bukrinsky,et al.  Chemokines and HIV replication , 1996, Nature.

[48]  J. Sodroski,et al.  The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry , 1996, Nature.

[49]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[50]  S. Chen,et al.  Intra- and extracellular immunization against HIV-1 infection with lymphocytes transduced with an AAV vector expressing a human anti-gp120 antibody. , 1996, Human gene therapy.

[51]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[52]  Marc Parmentier,et al.  A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors , 1996, Cell.

[53]  Ying Sun,et al.  The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates , 1996, Cell.

[54]  C. Broder,et al.  CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.

[55]  Bruce L. Levine,et al.  Antiviral Effect and Ex Vivo CD4+ T Cell Proliferation in HIV-Positive Patients as a Result of CD28 Costimulation , 1996, Science.

[56]  Virginia Litwin,et al.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.

[57]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[58]  Paul E. Kennedy,et al.  HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.

[59]  J. McCune,et al.  Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry , 1996, Antimicrobial agents and chemotherapy.

[60]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[61]  H. Günthard,et al.  A phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120. , 1994, The Journal of infectious diseases.

[62]  J. Albert,et al.  Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies. , 1994, Journal of acquired immune deficiency syndromes.

[63]  O. Bagasra,et al.  Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[64]  E. De Clercq,et al.  Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100 , 1994, Antimicrobial Agents and Chemotherapy.

[65]  D. Ho,et al.  Genotypic and phenotypic characterization of HIV-1 patients with primary infection. , 1993, Science.

[66]  S. Chen,et al.  Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[67]  O. Yamada,et al.  A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[68]  E. De Clercq,et al.  Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[69]  L. Moldawer,et al.  Effects of intravenous IL-8 administration in nonhuman primates. , 1992, Journal of immunology.

[70]  H. Schuitemaker,et al.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.

[71]  J. Rossi,et al.  Ribozymes as potential anti-HIV-1 therapeutic agents. , 1990, Science.

[72]  J. Moore,et al.  AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor , 1998, Nature Medicine.

[73]  D. Weissman,et al.  Inherited Resistance to HIV-1 Conferred by an Inactivating Mutation in CC Chemokine Receptor 5: Studies in Populations with Contrasting Clinical Phenotypes, Defined Racial Background, and Quantified Risk , 1997, Molecular medicine.